Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 170 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral Iron Clear all
Completed Phase 1 Interventional Results available

A Phase 1 Study of LY2787106 in Cancer and Anemia

NCT01340976
View directory record Official record
Conditions
Anemia
Interventions
LY2787106, Iron Supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

NCT00223977
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Sodium Ferric Gluconate Complex, Oral Iron
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2013 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

NCT02327546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548, Ferrous Sulfate
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women

NCT02038023
View directory record Official record
Conditions
Pregnancy
Interventions
Intravaneous iron(low molecular weight iron dextran)
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Enteral Iron Supplementation in Critical Illness

NCT00450177
View directory record Official record
Conditions
Anemic, Critically Ill Patients
Interventions
Ferrous Sulfate, Placebo Oral Tablet
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 2 Interventional

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

NCT04956263
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
Interventions
YG1699, Dapagliflozin
Drug
Lead sponsor
Youngene Therapeutics Inc., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

NCT03079869
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Ferric Citrate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 3, 2026, 5:51 AM EDT
Terminated Phase 1 Interventional

Safety of SP-420 in the Treatment of Transfusional Iron Overload

NCT04741542
View directory record Official record
Conditions
Iron Overload
Interventions
SP-420
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 3, 2026, 5:51 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen and Microvascular Function

NCT06043310
View directory record Official record
Conditions
Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions
Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

NCT04302896
View directory record Official record
Conditions
Medication Adherence, HIV
Interventions
dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
Drug
Lead sponsor
Rhonda Brand
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study for Patients With Poor Response to Deferasirox

NCT00749515
View directory record Official record
Conditions
Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions
Deferoxamine, Deferasirox, HIDA
Drug · Radiation
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in Subjects Who Display Postpartum Anemia

NCT00396292
View directory record Official record
Conditions
Anemia
Interventions
Oral iron tablets, VIT-45
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
Female only
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

NCT04269707
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Miami Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 3, 2026, 5:51 AM EDT
Recruiting Phase 3 Interventional

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

NCT04268849
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 3, 2026, 5:51 AM EDT
Recruiting Phase 3 Interventional

Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

NCT05179226
View directory record Official record
Conditions
Iron Deficiency, Anaemia in Children
Interventions
Ferric Derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
Up to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 3, 2026, 5:51 AM EDT
Terminated Phase 4 Interventional

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

NCT07053475
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
Interventions
Ferric Carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
Syed Hamza Mufarrih
Other
Eligibility
18 Years to 100 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bowling Green, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight Infants

NCT01125163
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Iron Supplement, multivitamin
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
24 Weeks to 32 Weeks
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

NCT00171210
View directory record Official record
Conditions
Transfusional Iron Overload in β-thalassemia
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

NCT03523117
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
16
States / cities
Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years

NCT05126901
View directory record Official record
Conditions
Anemia, Iron-deficiency
Interventions
Ferric Maltol, Ferrous sulfate
Drug
Lead sponsor
Shield Therapeutics
Industry
Eligibility
1 Month to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Saraland, Alabama • Homestead, Florida • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 3, 2026, 5:51 AM EDT
Terminated Phase 2 Interventional Results available

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

NCT01159067
View directory record Official record
Conditions
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
deferasirox
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Alternate Day Versus Daily Oral Iron Therapy in Adolescents

NCT05007899
View directory record Official record
Conditions
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Interventions
Ferrous sulfate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
9 Years to 22 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 3, 2026, 5:51 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)

NCT02499354
View directory record Official record
Conditions
Restless Legs Syndrome, Iron Deficiency Anemia
Interventions
Ferumoxytol intravenous, Ferrous sulfate
Drug
Lead sponsor
Auerbach Hematology Oncology Associates P C
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 3, 2026, 5:51 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

NCT06366698
View directory record Official record
Conditions
Iron Deficiency Anemia of Pregnancy
Interventions
Venofer 200 MG Per 10 ML Injection, Ferrous sulfate
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 3, 2026, 5:51 AM EDT